How diabetes can affect the tear film, corneal nerves and ocular surface.
When people think about diabetes and the eyes, they usually think about the retina. Diabetic retinopathy is well known.
But diabetes can also affect the front surface of the eye, including the tear film, corneal nerves and the tear-producing system. Dry eye disease is more common in people with diabetes, but the relationship is not as simple as:
“High blood sugar causes dry eyes.”
Diabetes can affect several parts of the ocular-surface system at the same time.
Diabetes is a systemic metabolic disease. Over time, chronic hyperglycemia and associated metabolic changes can affect nerves, blood vessels and tissues throughout the body. The ocular surface is no exception. Research has linked diabetes with changes involving:
So there is no single mechanism called “diabetic dry eye.” Different parts of the system may be affected in different people.
A lot. The cornea is one of the most densely innervated tissues in the human body. Those nerves do much more than allow you to feel something touching your eye. They participate in maintaining the corneal epithelium and in the neural feedback system connecting the ocular surface with blinking and tear secretion.
Diabetes can damage these nerves, a process known as diabetic corneal neuropathy. Studies have found reduced corneal nerve density and reduced corneal sensitivity in people with diabetes, particularly as neuropathy progresses.
Normally, the ocular surface constantly sends sensory information to the nervous system. When the surface becomes dry or disturbed, sensory nerves help trigger protective responses such as:
If corneal innervation is impaired, that feedback system may also be altered. This can contribute to abnormal tear function and ocular-surface homeostasis. So diabetes can potentially interfere not only with the tear film itself, but also with the communication system that helps regulate it.
Potentially, yes. This is one of the particularly interesting aspects of diabetic ocular-surface disease. If corneal sensitivity becomes reduced, the relationship between what is happening on the surface and what the person feels may become less straightforward. Diabetic corneal neuropathy is associated with reduced sensitivity as well as impaired epithelial healing.
That does not mean people with diabetes cannot experience severe dry-eye symptoms. They certainly can. Nor does reduced sensitivity occur in everyone with diabetes. The point is simply that symptom severity may not always perfectly reflect the amount of ocular-surface disturbance.
And importantly, symptom–sign mismatch is not unique to diabetes; neurosensory abnormalities are now recognized more broadly within dry-eye disease.
Neural Dysfunction: when the sensory system itself is part of the problem
It can. Research comparing people with and without diabetes has found reduced tear secretion in diabetic groups, although individual results vary considerably. A meta-analysis found lower basal and total tear secretion, shorter tear break-up time and reduced corneal sensitivity among people with diabetes compared with controls. More recent reviews describe several possible mechanisms, including changes in lacrimal-gland function and impaired neural regulation of tear secretion.
So diabetes can potentially contribute to an aqueous-deficient component of dry eye. But diabetes does not equal aqueous-deficient dry eye. Not every person with diabetes develops reduced tear production.
Yes. Studies have repeatedly reported reduced tear-film stability in people with diabetes. That may result from several overlapping factors rather than one isolated abnormality. Reduced tear secretion can matter. Changes in corneal sensation and blinking may matter. Ocular-surface inflammation and epithelial abnormalities may matter. And changes involving the lipid-producing meibomian glands may also contribute.
This is another reason diabetic dry eye should not automatically be classified as purely aqueous deficient.
Evidence suggests that meibomian-gland abnormalities can occur in people with diabetes, and recent reviews include altered meibomian gland function among potential contributors to diabetic ocular-surface disease. But we should be careful with causality. Finding MGD in a person with diabetes does not prove:
“Diabetes caused the MGD.”
MGD is extremely common and has many potential contributors. So the useful clinical question remains:
Meibomian Gland Dysfunction (MGD) — coming soon
The cornea can also be directly affected by diabetes. The term diabetic keratopathy describes a range of diabetes-associated corneal abnormalities. These can include:
This is related to dry eye, but it is not simply another name for dry eye. A person can have diabetes-related corneal changes that deserve attention in their own right.
The corneal epithelium is constantly renewing itself. Healthy corneal nerves help support this process. Diabetes can interfere with epithelial repair, and diabetic corneal neuropathy is associated with delayed wound healing.
This becomes particularly important after:
So when assessing the ocular surface in diabetes, the question is not only “Are the eyes dry?” It is also “Is the corneal surface healthy and healing normally?”
Chronic hyperglycemia is biologically relevant to many of the mechanisms involved in diabetic ocular-surface disease. Recent reviews describe links between hyperglycemia and oxidative stress, accumulation of advanced glycation end products, inflammation, microvascular changes and neural injury. However, translating that into an individual prediction is harder. A single glucose reading or HbA1c value cannot tell us exactly how severe someone’s dry eye should be.
Duration of diabetes, neuropathy, other complications, medications, age and independent ocular factors can all matter. So better metabolic control is important for diabetes management overall, but dry-eye severity cannot be calculated from blood glucose alone.
It can. Corneal nerve abnormalities have been associated with systemic diabetic neuropathy, and researchers have investigated corneal nerve measurements as potential markers of peripheral nerve damage. This connection makes biological sense because the cornea contains an extraordinarily rich network of small nerve fibers. But routine dry-eye examination is not a substitute for neurological evaluation of diabetic neuropathy.
The connection is useful because it reminds us that the nerves of the eye are part of the same body-wide nervous system affected by diabetes.
Fundamentally, the same principle applies as for everyone else: do not diagnose the mechanism from the systemic disease alone. A clinician may assess:
TFOS DEWS III specifically recognizes neural dysfunction alongside tear-film, eyelid and ocular-surface abnormalities as potential etiological drivers that should be identified individually.
So “the patient has diabetes” is useful medical context. It is not the dry-eye diagnosis.
Yes, although detailed nerve imaging is not part of every routine dry-eye examination. In vivo confocal microscopy can visualize the corneal sub-basal nerve plexus and has been widely used in research on diabetic corneal neuropathy. Researchers can examine characteristics such as nerve-fiber density and morphology. Corneal sensitivity can also be assessed clinically.
But these tests should answer a clinical question; not every person with diabetes and dry eye needs advanced corneal nerve imaging.
No. This is the same principle we used for autoimmune disease. A person with diabetes can also have:
Diabetes may be:
The ocular findings still matter.
Not necessarily. Good diabetes management is important for reducing systemic complications and limiting the effects of chronic hyperglycemia. But once dry-eye disease or diabetic ocular-surface abnormalities are present, they may also require specific ocular management. The treatment should therefore address the problems actually identified, for example tear-film deficiency, MGD, inflammation, epithelial disease or exposure, rather than assuming that systemic glucose management alone will resolve everything.
We will cover those treatments individually in What Can I Do About It?
Wolffsohn JS, et al. TFOS DEWS III: Diagnostic Methodology.
Current framework recognizing neural dysfunction alongside tear-film, eyelid and ocular-surface abnormalities as etiological drivers of DED.
Diabetic Dry Eye: Advances in Pathogenesis, Diagnostic Strategies, and Therapeutic Approaches.
Contemporary review of metabolic dysregulation, corneal neuropathy, tear secretion and tear-film instability in diabetic ocular-surface disease.
The Ocular Surface in Type 2 Diabetes: Pathophysiology and Impact of Anti-Diabetic Drugs.
Recent review of structural, biochemical and neuropathic ocular-surface changes associated with diabetes.
Diabetic Corneal Neuropathy: Pathogenic Mechanisms and Therapeutic Strategies.
Review of diabetes-associated changes in corneal nerve density, sensitivity and epithelial healing.
Meta-analysis and Review on Changes of Tear Function and Corneal Sensitivity in Diabetic Patients.
Meta-analysis reporting lower tear secretion, shorter tear-film break-up time and reduced corneal sensitivity in diabetic groups.